Lithium carbonate as treatment in patients with amyotrophic lateral sclerosis carrying the UNC13A at risk genotype KU Leuven
Over the last 2 decades, more than 50 large randomize controlled trial in amyotrophic lateral sclerosis (ALS) were negative. One of the reasons for this lack of succes is the high degree of heterogeneity in ALS. Currenlty, all patients (with very different disease onset-progressionetiologies) are lumped together. In order to improve the quality of trial design, novel strategies to identify more homogeneous patient pools are urgently ...